Technical trend analysis in Eli Lilly stock forecast 2030 suggests a long-term uptrend channel, with potential price retracements offering accumulation opportunities for institutional and retail investors alike. These current drugs and possible new ones, along with forecasts for massive market growth (to reach $100 billion by 2030, according to Goldman Sachs Research), suggest Lilly will continue to benefit from significant revenue growth in the years to come. CoinCodex sees Eli Lilly reaching an average estimated value of $1,030.81 per share, suggesting a 37% gain from current levels. The company’s pipeline, acquisitions, and successful drugs may push the stock price higher. Eli Lilly stock forecast 2030 often aligns with bullish price targets under scenarios of sustained double-digit EPS growth, supported by efficient expense management and strong gross margins above 75%.